People · Operator
Named in public records as an officer, director or promoter · active 2019–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neurelis, Inc. | — | Biotechnology | Series D+ | $221.8M | $3.8B | 2019 |
Stephen F. Cartt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen F. Cartt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David F Hale | 1 | 16 |
| Cam L. Garner | 1 | 11 |
| William R. LaRue | 1 | 3 |
| David A. Gonyer | 1 | 2 |
| Yong C. Zhang | 1 | 1 |
| Kevin C. Li | 1 | 1 |
| Cam C. Garner | 1 | 1 |
| Huaizheng C. Peng | 1 | 1 |
| Priyanka F. Belawat | 1 | 1 |
| George F. Stuart | 1 | 1 |
| Kevin L. Li | 1 | 1 |
| Craig C. Chambliss | 1 | 1 |
| Yong L. Zhang | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.